Skip to main content

ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc. is an American biopharmaceutical enterprise that focuses on the discovery, development, and commercialization of small-molecule drugs for central nervous system (CNS) disorders and rare neurological conditions. The company operates through a single biopharmaceutical segment, having successfully commercialized approved therapies including Nuplazid (pimavanserin) for Parkinson's disease psychosis and Daybue (trofinetide) for Rett syndrome. Its primary revenue drivers stem from direct commercial sales of Nuplazid and Daybue to specialty pharmacies, healthcare distributors, and medical providers in the United States. ACADIA Pharmaceuticals holds a pioneer position in neurological and neuropsychiatric medicine, delivering target treatments for underserved CNS conditions. The enterprise serves neurologists, psychiatrists, rare disease specialists, patients, and care partners. The company focuses on expanding commercial market access for its commercial products, advancing clinical trials for Alzheimer's disease psychosis and other neurodevelopmental indications, and expanding its CNS drug pipeline. ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California, United States, and its common stock is publicly listed and traded on the Nasdaq Global Select Market.

5 of the funds FundTelligence covers report a position in ACADIA Pharmaceuticals.

Legal name
ACADIA Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
5
Exposure themes
Mental Health, Psychiatry, Schizophrenia & Psychosis

Funds holding ACADIA Pharmaceuticals

Loading...